200 related articles for article (PubMed ID: 21340468)
41. The role of kinin B1 and B2 receptors in the scratching behaviour induced by proteinase-activated receptor-2 agonists in mice.
Costa R; Manjavachi MN; Motta EM; Marotta DM; Juliano L; Torres HA; Pesquero JB; Calixto JB
Br J Pharmacol; 2010 Feb; 159(4):888-97. PubMed ID: 20067469
[TBL] [Abstract][Full Text] [Related]
42. Suppression by the cannabinoid CB1 receptor antagonist, rimonabant, of the reinforcing and motivational properties of a chocolate-flavoured beverage in rats.
Maccioni P; Pes D; Carai MA; Gessa GL; Colombo G
Behav Pharmacol; 2008 May; 19(3):197-209. PubMed ID: 18469537
[TBL] [Abstract][Full Text] [Related]
43. Rimonabant, a cannabinoid CB1 receptor antagonist, attenuates mechanical allodynia and counteracts oxidative stress and nerve growth factor deficit in diabetic mice.
Comelli F; Bettoni I; Colombo A; Fumagalli P; Giagnoni G; Costa B
Eur J Pharmacol; 2010 Jul; 637(1-3):62-9. PubMed ID: 20399204
[TBL] [Abstract][Full Text] [Related]
44. Involvement of spinal cannabinoid receptors in the antipruritic effects of WIN 55,212-2, a cannabinoid receptor agonist.
Bilir KA; Anli G; Ozkan E; Gunduz O; Ulugol A
Clin Exp Dermatol; 2018 Jul; 43(5):553-558. PubMed ID: 29424035
[TBL] [Abstract][Full Text] [Related]
45. Novel 3-substituted rimonabant analogues lack Δ(9) -tetrahydrocannabinol-like abuse-related behavioural effects in mice.
Walentiny D; Vann R; Mahadevan A; Kottani R; Gujjar R; Wiley J
Br J Pharmacol; 2013 May; 169(1):10-20. PubMed ID: 23297801
[TBL] [Abstract][Full Text] [Related]
46. Low dosage of rimonabant leads to anxiolytic-like behavior via inhibiting expression levels and G-protein activity of kappa opioid receptors in a cannabinoid receptor independent manner.
Zádor F; Lénárt N; Csibrány B; Sántha M; Molnár M; Tuka B; Samavati R; Klivényi P; Vécsei L; Marton A; Vizler C; Nagy GM; Borsodi A; Benyhe S; Páldy E
Neuropharmacology; 2015 Feb; 89():298-307. PubMed ID: 25446673
[TBL] [Abstract][Full Text] [Related]
47. The cannabinoid CB1 receptor antagonist AM251 does not modify methamphetamine reinstatement of responding.
Boctor SY; Martinez JL; Koek W; France CP
Eur J Pharmacol; 2007 Sep; 571(1):39-43. PubMed ID: 17628534
[TBL] [Abstract][Full Text] [Related]
48. Delta9-THC induced hyperphagia and tolerance assessment: interactions between the CB1 receptor agonist delta9-THC and the CB1 receptor antagonist SR-141716 (rimonabant) in rats.
Järbe TU; DiPatrizio NV
Behav Pharmacol; 2005 Sep; 16(5-6):373-80. PubMed ID: 16148441
[TBL] [Abstract][Full Text] [Related]
49. CB1 cannabinoid receptor-mediated modulation of food intake in mice.
Wiley JL; Burston JJ; Leggett DC; Alekseeva OO; Razdan RK; Mahadevan A; Martin BR
Br J Pharmacol; 2005 Jun; 145(3):293-300. PubMed ID: 15778743
[TBL] [Abstract][Full Text] [Related]
50. AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studies.
Seely KA; Brents LK; Franks LN; Rajasekaran M; Zimmerman SM; Fantegrossi WE; Prather PL
Neuropharmacology; 2012 Oct; 63(5):905-15. PubMed ID: 22771770
[TBL] [Abstract][Full Text] [Related]
51. Reversal of SR 141716A-induced head-twitch and ear-scratch responses in mice by delta 9-THC and other cannabinoids.
Janoyan JJ; Crim JL; Darmani NA
Pharmacol Biochem Behav; 2002; 71(1-2):155-62. PubMed ID: 11812518
[TBL] [Abstract][Full Text] [Related]
52. The cannabinoid CB1 receptor antagonists rimonabant (SR141716) and AM251 directly potentiate GABA(A) receptors.
Baur R; Gertsch J; Sigel E
Br J Pharmacol; 2012 Apr; 165(8):2479-84. PubMed ID: 21470203
[TBL] [Abstract][Full Text] [Related]
53. Cannabinoid withdrawal in mice: inverse agonist vs neutral antagonist.
Tai S; Nikas SP; Shukla VG; Vemuri K; Makriyannis A; Järbe TU
Psychopharmacology (Berl); 2015 Aug; 232(15):2751-61. PubMed ID: 25772338
[TBL] [Abstract][Full Text] [Related]
54. Involvement of histamine H3 receptors in scratching behaviour in mast cell-deficient mice.
Hossen MA; Sugimoto Y; Kayasuga R; Kamei C
Br J Dermatol; 2003 Jul; 149(1):17-22. PubMed ID: 12890190
[TBL] [Abstract][Full Text] [Related]
55. Antagonism of ∆⁹-THC induced behavioral effects by rimonabant: time course studies in rats.
Järbe TU; Gifford RS; Makriyannis A
Eur J Pharmacol; 2010 Dec; 648(1-3):133-8. PubMed ID: 20854804
[TBL] [Abstract][Full Text] [Related]
56. Delta(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB(1) receptor antagonist/inverse agonist SR 141716A.
Darmani NA
Neuropsychopharmacology; 2001 Feb; 24(2):198-203. PubMed ID: 11120402
[TBL] [Abstract][Full Text] [Related]
57. Pharmacological evaluation of the natural constituent of Cannabis sativa, cannabichromene and its modulation by Δ(9)-tetrahydrocannabinol.
DeLong GT; Wolf CE; Poklis A; Lichtman AH
Drug Alcohol Depend; 2010 Nov; 112(1-2):126-33. PubMed ID: 20619971
[TBL] [Abstract][Full Text] [Related]
58. Hippocampal endocannabinoids inhibit spatial learning and limit spatial memory in rats.
Robinson L; McKillop-Smith S; Ross NL; Pertwee RG; Hampson RE; Platt B; Riedel G
Psychopharmacology (Berl); 2008 Jul; 198(4):551-63. PubMed ID: 18049812
[TBL] [Abstract][Full Text] [Related]
59. Inhibition of improgan antinociception by the cannabinoid (CB)(1) antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A): lack of obligatory role for endocannabinoids acting at CB(1) receptors.
Hough LB; Nalwalk JW; Stadel R; Timmerman H; Leurs R; Paria BC; Wang X; Dey SK
J Pharmacol Exp Ther; 2002 Oct; 303(1):314-22. PubMed ID: 12235266
[TBL] [Abstract][Full Text] [Related]
60. Effects of AM1346, a high-affinity CB1 receptor selective anandamide analog, on open-field behavior in rats.
Järbe TU; DiPatrizio NV; Li C; Makriyannis A
Behav Pharmacol; 2007 Nov; 18(7):673-80. PubMed ID: 17912052
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
